Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care

Abstract Objective To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin. Design Prospective open cohort study. Setting UK general practices contributing to QResearch or Clinical Practice Research Datalink. Participants 132 231 warfarin, 7744 dabigatran, 37 863 rivaroxaban, and 18 223 apixaban users without anticoagulant prescriptions for 12 months before study entry, subgrouped into 103 270 patients with atrial fibrillation and 92 791 without atrial fibrillation between 2011 and 2016. Main outcome measures Major bleeding leading to hospital admission or death. Specific sites of bleeding and all cause mortality were also studied. Results In patients with atrial fibrillation, compared with warfarin, apixaban was associated with a decreased risk of major bleeding (adjusted hazard ratio 0.66, 95% confidence interval 0.54 to 0.79) and intracranial bleeding (0.40, 0.25 to 0.64); dabigatran was associated with a decreased risk of intracranial bleeding (0.45, 0.26 to 0.77). An increased risk of all cause mortality was observed in patients taking rivaroxaban (1.19, 1.09 to 1.29) or on lower doses of apixaban (1.27, 1.12 to 1.45). In patients without atrial fibrillation, compared with warfarin, apixaban was associated with a decreased risk of major bleeding (0.60, 0.46 to 0.79), any gastrointestinal bleeding (0.55, 0.37 to 0.83), and upper gastrointestinal bleeding (0.55, 0.36 to 0.83); rivaroxaban was associated with a decreased risk of intracranial bleeding (0.54, 0.35 to 0.82). Increased risk of all cause mortality was observed in patients taking rivaroxaban (1.51, 1.38 to 1.66) and those on lower doses of apixaban (1.34, 1.13 to 1.58). Conclusions Overall, apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were, however, associated with increased risks of all cause mortality compared with warfarin.

[1]  G. Lip.  Atrial fibrillation in 2011: Stroke prevention in AF. , 2012, Nature reviews. Cardiology.

[2]  J. West,et al.  Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions , 2011, Gut.

[3]  G. Lip,et al.  Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study , 2017, JAMA cardiology.

[4]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[5]  R J Glynn,et al.  Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs , 2014, Journal of internal medicine.

[6]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[7]  Charli Spier.  Deprivation. , 2019, Health visitor.

[8]  A. Maguire,et al.  Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care , 2016, BMJ Open.

[9]  L. Køber,et al.  Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study , 2013, BMJ Open.

[10]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[11]  E. Kuipers,et al.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.

[12]  Louise J Jackson,et al.  Effects of antenatal diet and physical activity on maternal and fetal outcomes: individual patient data meta-analysis and health economic evaluation. , 2017, Health technology assessment.

[13]  S. de Lusignan,et al.  Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care , 2018, British Medical Journal.

[14]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[15]  Hannah R Rothstein,et al.  A basic introduction to fixed‐effect and random‐effects models for meta‐analysis , 2010, Research synthesis methods.

[16]  S. Kohsaka,et al.  Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data , 2017, Current medical research and opinion.

[17]  G. Lip,et al.  Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2017, British Medical Journal.

[18]  D G Altman,et al.  Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.

[19]  Carol Coupland,et al.  Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores , 2014, BMJ : British Medical Journal.

[20]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[21]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[22]  S. Sorensen,et al.  Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. , 2014, Clinical therapeutics.

[23]  M. Lamberts,et al.  Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients , 2017, Journal of the American Heart Association.

[24]  N. Abraham,et al.  Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study , 2015, BMJ : British Medical Journal.

[25]  R. Hubbard,et al.  Does concurrent prescription of selective serotonin reuptake inhibitors and non‐steroidal anti‐inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? , 2005, Alimentary pharmacology & therapeutics.

[26]  I. Hernandez,et al.  Risk of bleeding with dabigatran in atrial fibrillation. , 2015, JAMA internal medicine.

[27]  A. Lazo-Langner,et al.  New oral anticoagulants , 2013, Canadian Medical Association Journal.

[28]  P. Noseworthy,et al.  Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. , 2017, Gastroenterology.

[29]  T. Villines,et al.  A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system , 2015, Thrombosis and Haemostasis.

[30]  D. Singer,et al.  Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[31]  M. Goldacre,et al.  Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study , 2011, Alimentary pharmacology & therapeutics.

[32]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[33]  G. Lip,et al.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2016, British Medical Journal.

[34]  M. Brookhart,et al.  Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study , 2015, Journal of the American Heart Association.

[35]  Sonal Singh,et al.  Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study , 2015, BMJ : British Medical Journal.

[36]  G. Caleb Alexander,et al.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.

[37]  Evangelos Kontopantelis,et al.  Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study , 2018, BMJ Open.

[38]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[39]  J. Sterne,et al.  Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. , 2017, Health Technology Assessment.

[40]  J. Sterne,et al.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. , 2017, Health technology assessment.

[41]  A. Amin,et al.  Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population , 2017, Current medical research and opinion.

[42]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[43]  G. Lip,et al.  Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin , 2016, Thrombosis and Haemostasis.